Karuna Therapeutics Inc

Karuna Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. engages in business of research and development of therapies utilizing muscarinic cholinergic receptors to treat psychosis and cognitive impairment in numerous central nervous system disorders. The company was founded by Andrew Miller, Eric Elenko, and Peter Jeffrey Conn in July 2009 and is headquartered in Boston, MA.

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Karuna Therapeutics reports positive trial results and strong financial outlook

Karuna Therapeutics is making significant progress in its key programs, with positive trial results and a focus on expanding its pipeline. Despite challenges in trial timelines and increased expenses, the company's strong financial position and strategic priorities position it well for future growth.

Karuna Therapeutics reports robust Q2 performance and eyes new indications

Karuna Therapeutics reported strong financials, progress on NDA submission, and ongoing Phase III programs.
The company's focus on cognitive benefits, broader efficacy, and potential new indications showcases strategic growth initiatives.
Challenges include competitive dynamics in Alzheimer's trials and uncertainties in the applicability of KarXT in certain patient populations.
Opportunities lie in exploring new indications, demonstrating cognitive benefits, and enhancing efficacy in mood and anxiety disorders.

Karuna Therapeutics excels in Q3, eyes global expansion for KarXT

Karuna Therapeutics demonstrated strong performance in Q3 with a focus on KarXT Phase III programs and NDA submission, supported by a healthy financial position.
Strategic strengths lie in maximizing KarXT value, positive payer interactions, and broad-based commercial strategies, while challenges include managing expenses and operational considerations.
Opportunities for growth include expanding the TRPC4/5 program, leveraging favorable mental health trends, and pursuing international market partnerships for KarXT.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Karuna Therapeutics is a biopharmaceutical company that develops treatments for psychiatric and neurological conditions. Karuna Therapeutics creates drugs that can significantly improve the lives of people who suffer from neurological and psychiatric illnesses, with a particular focus on schizophrenia and the behavioral symptoms of Alzheimer's disease. The company is skilled in neuroscience and has creative ideas for finding and developing new drugs. Karuna Therapeutics is advancing a pipeline of innovative drugs since its inception with the aim of significantly improving the lives of people suffering from these difficult conditions.

BOSTON--( BUSINESS WIRE )--Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced the appointment of Will Kane as chief commercial officer (CCO), effective February 6, 2023.

Karuna Therapeutics Appoints William P. Kane as Chief Commercial Officer

BOSTON--( BUSINESS WIRE )--Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced that Bill Meury, president and chief executive officer, will present at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023, at 9:00 a.m. PST (12:00 p.m. EST).

Karuna Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

NEW YORK , Dec. 29, 2022 /PRNewswire/ -- Moore Kuehn, PLLC, a securities law firm located on Wall Street, is investigating whether certain officers and directors of Karuna Therapeutics, Inc. (NASDAQ: KRTX) breached their fiduciary duties to shareholders.  The investigation concerns potential self-dealing.

Moore Kuehn, PLLC Encourages Investors of Karuna Therapeutics, Inc. to Contact Law Firm

Arvinas Inc

Axsome Therapeutics

Denali Therapeutics

Fate Therapeutics

Chart Industries

Rocket Pharma

Analysts say a tough 2022 has left these small-cap stocks priced for outperformance in the new year and beyond.

7 Best Small-Cap Stocks to Buy for 2022 and Beyond

Karuna Therapeutics, Inc. transitioned a new CEO in yesterday, with the former chief now president of R&D. Questions now arise on Karuna Therapeutics' suitability as a takeover candidate.

Karuna: Acquisition Prospects Thin With CEO Change

Karuna Therapeutics Inc KRTX shares are trading lower by 11.63% to $200.56 going into the close of Tuesday's session after the company announced a CEO transition.

Why Karuna Therapeutics Shares Are Trading Sharply Lower - Karuna Therapeutics (NASDAQ:KRTX)

BOSTON--( BUSINESS WIRE )--Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced the appointment of Bill Meury as president and chief executive officer (CEO) and a member of the Company's board, effective January 3, 2023. Mr. Meury will succeed Steve Paul, M.D., the current president, chief executive officer and chairman, who will transition to president of research and development and chief scientific officer and continue to serve as a member of the board following the effective date. At that time, Christopher Coughlin, the Company's lead independent director, will assume the role of chairman of the board.

Karuna Therapeutics Appoints Bill Meury as President and Chief Executive Officer

Altimmune

Viking Therapeutics

My 3 Top Biotech Stock Picks for 2023

Karuna Therapeutics (KRTX) reports dismal third-quarter 2022 results. The company misses estimates for earnings and sales.

Karuna Therapeutics (KRTX) Posts Wider-Than-Expected Q3 Loss

Karuna Therapeutics, Inc. (KRTX) delivered earnings and revenue surprises of -19.60% and 99.19%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Karuna Therapeutics, Inc. (KRTX) Reports Q3 Loss, Misses Revenue Estimates

BOSTON--(BUSINESS WIRE)---- $KRTX--Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced financial results for the third quarter of 2022 and provided a general business update.

Karuna Therapeutics Reports Third Quarter 2022 Financial Results and Provides General Business Updates

BOSTON--(BUSINESS WIRE)---- $KRTX--Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced that Troy Ignelzi, chief financial officer of Karuna Therapeutics, will participate in a fireside chat at the Jefferies 2022 London Healthcare Conference on Wednesday, November 16, 2022, at 3:50 p.m.

Karuna Therapeutics to Present at the Jefferies 2022 London Healthcare Conference

AbbVie

Alnylam Pharmaceuticals

Amgen

Biogen

Pfizer

Zai Lab Ltd.

Recent clinical successes and M&A could bring interest back to biotechnology, especially among mid-capitalization names with derisked or approved products. Restructuring, corporate activity, and COVID-19 revenues have significantly improved the funding positions of many large biopharma companies, providing ample dry powder for M&A.

Deal Activity Could Jumpstart Biotechnology

Reata Pharmaceuticals

The biotech sector is down this year, but these two biopharmaceutical stocks have delivered strong returns.

2 On-Fire Biotech Stocks That Are Crushing the Bear Market

PARAMUS, N.J.--(BUSINESS WIRE)--PsychoGenics Inc. (“PsychoGenics” or the “Company”), a leader in AI-enabled phenotypic drug discovery and preclinical CRO services, today announced that clinical-stage biopharmaceutical company Karuna Therapeutics, Inc., (NASDAQ: KRTX) has extended its drug discovery collaboration with the Company aimed at identifying potential novel drug candidates for the treatment of severe neuropsychiatric disorders. The initial multi-year agreement, announced in July 2020, a

PsychoGenics Announces Extension of Ongoing Drug Discovery Collaboration with Karuna Therapeutics

Akero Therapeutics Inc

bluebird bio

Chemocentryx

Forma Therapeutics Holdings

iShares Nasdaq Biotechnology ETF

Novo Nordisk

Rhythm Pharmaceuticals

SPDR S&P Biotech ETF

Biotechs are relatively better positioned in this fourth quarter compared to the broader market. Path of interest rates is clearer for 2022 and the Fed is closer to a pause early next year as it calibrates down its response from a hammer approach.

Biotech Stocks Well-Positioned For Fourth Quarter

BOSTON--(BUSINESS WIRE)---- $KRTX--Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced that data from the Phase 3 EMERGENT-2 trial of KarXT in schizophrenia will be shared at the 35th European College of Neuropsychopharmacology (ECNP) Congress, to be held October 15-18, 2022, in Vienna, Austria. A poster presentation and symposium will incl

Karuna Therapeutics to Present Data from the Phase 3 EMERGENT-2 Trial of KarXT in Schizophrenia at the 35th European College of Neuropsychopharmacology (ECNP) Congress

Calumet Inc

Hudson Technologies

iRhythm Technologies

Lantheus Holdings

Liquidia Technologies Inc

Veru

Before jumping directly into momentum stocks worth buying now, it's important to understand what momentum trading is. As the name implies, momentum trading relies on reacting to the current movement of a stock or sector.

7 Momentum Stocks to Buy Now for Extraordinary Gains

Karuna produced excellent data from its phase 3 trial. They have a boatload of cash.

Karuna Therapeutics: This Ship Has Sailed

Karuna Therapeutics, Inc. (KRTX) reported earnings 30 days ago. What's next for the stock?

Why Is Karuna Therapeutics, Inc. (KRTX) Up 8.4% Since Last Earnings Report?

Biotech stocks are scorching right now. But the best of the best have strong gains.

10 Biotech Stocks Are Up 40% Or More This Year, Including Karuna, Axsome And Others

These three biotech companies could be headed for a buyout soon.

3 Biopharmas on Buyout Watch

Apellis Pharma

Beam Therapeutics

Global Blood Therapeutics

Intellia Therapeutics

PTC Therapeutics

Repligen

Twist Bioscience Corp

Barron's screened for stocks such as Global Blood Therapeutics and Karuna Therapeutics that popped this summer.

10 Stocks Driving the Biotech Resurgence

While researching about Karuna Therapeutics Inc. ( KRTX , Financial), I liked what I read so I decided to take a small position in the Boston-based biopharmaceutical company. Here I will invoke a common refrain: “If I had only bought more.

Karuna Therapeutics Shareholders Hit the Jackpot

Karuna Therapeutics (KRTX) is progressing well with its pipeline development. KRTX's lead candidate meets late-stage study goals as a potential treatment for adults with schizophrenia.

Karuna (KRTX) Stock Skyrockets 98.7% in a Month: Here's Why

News for Karuna Therapeutics Inc Stock (KRTX)